MED12 and lymphangioma: Makinen et al. have suggested based on bioinformatics pathway analysis [17] that MED12 mutations could be involved in LM development through activation of the Wnt/β-catenin pathway; the Wnt/β-catenin target genes being among the genes positively regulated by MED12 [25]–[26].